Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis

Abstract

Abstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.

Keywords

• acute myeloid leukemia
• allogeneic stem cell transplantation
• FLT3 mutation
• leukemia cutis
• relapse
• sorafenib